Eli Lilly Reports Strong Q3 Growth Amid Weight Loss Drug Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7h ago
0mins
Source: Fool
- Significant Revenue Growth: Eli Lilly's Q3 revenue surged 54% year-over-year to $17.6 billion, showcasing strong momentum in its weight loss and diabetes drug sectors, further solidifying its market leadership.
- Earnings Per Share Surge: Q3 earnings per share skyrocketed from $1.07 in 2024 to $6.21 in 2025, reflecting a staggering 480% year-over-year increase, highlighting the transformative potential and profitability of the company's product portfolio.
- Mounjaro Sales Surge: Eli Lilly's flagship drug Mounjaro achieved sales of $15.55 billion in the first three quarters of 2025, a 94% increase, indicating robust demand and growth potential in the market.
- Optimistic Guidance: The company raised its full-year 2025 revenue guidance to $63 billion to $63.5 billion, anticipating nearly 40% annual growth, further demonstrating its competitive edge and capacity for sustained growth in the pharmaceutical industry.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1062.750
Low
950.00
Averages
1192
High
1500
Current: 1062.750
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
